April 10, 2014
The Ministry of Health, Labor and Welfare (MHLW) did not propose the NHI listing of Takeda Pharmaceutical’s obesity drug OBLEAN (cetilistat) at a general assembly of its key advisory panel on April 9, saying it needs additional data from the...read more